低危肺栓塞患者急诊科出院的随机对照研究
本研究为多中心、开放标签随机试验,纳入Hestia标准定义的低危肺栓塞成人患者,随机分为急诊早期出院利伐沙班组或标准治疗组。主要终点为随机分组后30天内初始住院小时数加上因出血或静脉血栓栓塞再住院小时数。结果显示早期出院组初始住院时间为4.8小时,标准治疗组为33.6小时,平均差为-28.8小时(95%CI -42.55至-15.12小时);90天总住院时间早期出院组为19.2小时,标准治疗组为43.2小时,平均差为26.4小时(95%CI -46.97至-3.34小时)。90天内两组均无出血事件、复发性VTE或死亡,复合安全终点差异为0.005(95%CI -0.18至0.19)。总费用早期出院组为1496美元,标准治疗组为4234美元,中位差为2496美元(95%CI -2999至-2151美元)。
要点
- 低危肺栓塞患者(Hestia标准)急诊早期出院使用利伐沙班,30天初始住院时间4.8小时 vs 标准治疗33.6小时,平均差-28.8小时(95%CI -42.55至-15.12)。
- 90天总住院时间早期出院组19.2小时 vs 标准治疗组43.2小时,平均差26.4小时(95%CI -46.97至-3.34小时)。
- 90天内两组均无出血事件、复发性VTE或死亡,复合安全终点差异0.005(95%CI -0.18至0.19)。
- 总费用早期出院组1496美元 vs 标准治疗组4234美元,中位差2496美元(95%CI -2999至-2151美元)。
- 共114例随机,早期出院51例,标准治疗63例;112例(98.2%)至少接受一剂研究药物,99例(86.8%)完成研究。
适用人群与场景
- 成人低危肺栓塞患者,低危定义采用Hestia标准。
诊断标准与关键阈值
- 低危肺栓塞采用Hestia标准定义。
处置流程与药物剂量
- 早期出院组:急诊出院并给予利伐沙班(原文未写明剂量、频次及疗程)。
- 标准治疗组:按常规标准治疗(原文未写明具体方案)。
研究设计与关键结果
- 多中心、开放标签随机试验,纳入114例低危肺栓塞患者,早期出院组51例,标准治疗组63例。
- 30天初始住院时间:早期出院组4.8小时 vs 标准治疗组33.6小时,平均差-28.8小时(95%CI -42.55至-15.12小时)。
- 90天总住院时间(任何原因):早期出院组19.2小时 vs 标准治疗组43.2小时,平均差26.4小时(95%CI -46.97至-3.34小时)。
- 90天内两组均无出血事件、复发性VTE或死亡;复合安全终点(大出血、临床相关非大出血和死亡)两组差异0.005(95%CI -0.18至0.19)。
- 总费用:早期出院组1496美元 vs 标准治疗组4234美元,中位差2496美元(95%CI -2999至-2151美元)。
证据类型、等级与局限
- 证据类型:多中心、开放标签随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于Hestia标准定义的低危肺栓塞成人患者,急诊早期出院并使用利伐沙班与标准治疗相比结局相似,且30天内总住院时间和费用更少。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Hospitalization for low-risk pulmonary embolism (PE) is common, expensive, and of questionable benefit.
OBJECTIVE: The objective was to determine if low-risk PE patients discharged from the emergency department (ED) on rivaroxaban require fewer hospital days compared to standard of care (SOC).
METHODS: Multicenter, open-label randomized trial in low-risk PE defined by Hestia criteria. Adult subjects were randomized to early ED discharge on rivaroxaban or SOC. Primary outcome was total number of initial hospital hours, plus hours of hospitalization for bleeding or venous thromboembolism (VTE), 30 days after randomization. A 90-day composite safety endpoint was defined as major bleeding, clinically relevant nonmajor bleeding, and mortality.
RESULTS: Of 114 randomized subjects, 51 were early discharge and 63 were SOC. Of 112 (98.2%) receiving at least one dose of study drug, 99 (86.8%) completed the study. Initial hospital LOS was 4.8 hours versus 33.6 hours, with a mean difference of -28.8 hours (95% confidence interval [CI] = -42.55 to -15.12 hours) for early discharge versus SOC, respectively. At 90 days, mean total hospital days (for any reason) were less for early discharge than SOC, 19.2 hours versus 43.2 hours, with a mean difference of 26.4 hours (95% CI = -46.97 to -3.34 hours). At 90 days, there were no bleeding events, recurrent VTE, or deaths. The composite safety endpoint was similar in both groups, with a difference in proportions of 0.005 (95% CI = -0.18 to 0.19). Total costs were $1,496 for early discharge and $4,234 for SOC, with a median difference of $2,496 (95% CI = -$2,999 to -$2,151).
CONCLUSIONS: Low-risk ED PE patients receiving early discharge on rivaroxaban have similar outcomes to SOC, but fewer total hospital days and lower costs over 30 days.
参考来源
- Frank Peacock W, Coleman CI, Diercks DB, et al. Emergency Department Discharge of Pulmonary Embolus Patients. Acad Emerg Med. 2018. PMID: 29757489. doi:10.1111/acem.13451
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。